Short- and long-term safety of glaucoma drugs

Expert Opinion on Drug Safety

Volumn 1, Issue 2, 2002, Pages 181-194

  Schuman, Joel S ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adrenergic agonists; adrenergic blockers; carbonic anhydrase inhibitors; cholinergic agents; glaucoma; long term safety; ocular hypotensive lipids

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; TIMOLOL;

DRUG EFFECT; EXPERT WITNESS; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; REVIEW; SAFETY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBONIC ANHYDRASE INHIBITORS; EXPERT TESTIMONY; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; SAFETY; TIMOLOL;

EID: 0038090064     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.2.181     Document Type: Review

References (164)

1. MUNIER A, GUNNING T, KENNY D, O'KEEFE M: Causes of blindness in the adult population of the Republic of Ireland. Br. J. Ophthalmol. (1998) 82:6.
2. BLOMDAHL S, CALISSENDORFF B, TENGROTH B, WALLIN O: Blindness in glaucoma patients. Acta Ophthalmol. Scand. (1997) 75:5.
3. QUIGLEY H, TIELSCH J, KATZ J, SOMMER A: Rate of progression in openangle glaucoma estimated from crosssectional prevalence of visual field damage. Am. J. Ophthalmol. (1996) 122:3.
4. QUIGLEY H, ADDICKS E, GREEN W, MAUMENEE A: Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch. Ophthalmol. (1981) 91:573-587.
5. SOMMER A, TIELSCH J, KATZ J et al.: Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol. (1991) 109:1090-1095.
6. COLLABORATIVE NORMALTENSION GLAUCOMA STUDY GROUP: The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. (1998) 126:498-505.
7. COLLABORATIVE NORMALTENSION GLAUCOMA STUDY GROUP: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. (1998) 126:487-497.
8. HOYNG P, VAN BEEK LM: Pharmacological therapy for glaucoma: a review. Drugs (2000) 59:411-434. (Pubitemid 30213853)
9. SCHUMAN J: Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin. Ther. (2000) 22:167-208. (Pubitemid 30152099)
10. GOTTFREDSDOTTIR M, ALLINGHAM R, SHIELDS M: Physicians' guide to interactions between glaucoma and systemic medications. J. Glaucoma (1997) 6:377-383. (Pubitemid 28051073)
11. ALVAN G, CALISSENDORFF B, SEIDEMAN P, WIDMARK K, WIDMARK G: Absorption of ocular timolol. Clin. Pharmacokinet. (1980) 5:95-100. (Pubitemid 11254708)
12. WATSON P, BARNETT M, PARKER V, HAYBITTLE J: A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br. J. Ophthalmol. (2001) 85:962-968. (Pubitemid 32707429)
13. ZIMMERMAN T, KASS M, YABLONSKI M, BECKER B: Timolol maleate: efficacy and safety. Arch. Ophthalmol. (1979) 97:656-658.
14. ZIMMERMAN T, KAUFMAN H: Timolol, dose response and duration of action. Arch. Ophthalmol. (1977) 95:605-607. (Pubitemid 8263099)
15. ZIMMERMAN T, KAUFMAN H: Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch. Ophthalmol. (1977) 95:601-604. (Pubitemid 8263098)
16. RITCH R, HARGETT N, PODOS S: The effect of 1.5% timolol maleate on intraocular pressure. Acta Ophthalmol. (Copenh.) (1978) 56:6-10. (Pubitemid 8281167)
17. BOGER W III, STEINERT R, THOMAS J: Timolol in the therapy of "ocular hypertension". Surv. Ophthalmol. (1980) 25:195-202.
18. OBSTBAUM S, GALIN M, KATZ I: Timolol: effect on intraocular pressure in chronic open-angle glaucoma. Ann. Ophthalmol. (1978) 10:1347-1351. (Pubitemid 9034462)
19. DRANCE S: A comparison of the effects of betaxolol, timolol and pilocarpine on visual function in patients with open-angle glaucoma. J. Glaucoma (1998) 7:247-252. (Pubitemid 29149817)
20. STEWART W, COHEN J, NETLAND P, WEISS H, NUSSBAUM L: Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am. J. Ophthalmol. (1997) 124:498-505. (Pubitemid 27425874)
21. DUBINER H, HILL R, KAUFMAN H, KEATES E et al.: Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma. Am. J. Ophthalmol. (1996) 121:522-528. (Pubitemid 26135860)
22. THE LEVOBUNOLOL STUDY GROUP: Levobunolol. A four-year study of efficacy and safety in glaucoma treatment. Ophthalmology (1989) 96:642-645.
23. OBER M, SCHARRER A, DAVID R et al.: Long-term ocular hypotensive effect of levobunolol: results of a one-year study. Br. J. Ophthalmol. (1985) 69:593-599. (Pubitemid 15229316)
24. AIRAKSINEN P, VALLE O, TAKKI K, KLEMETTI A: Timolol treatment of chronic open-angle glaucoma and ocular hypertension. A 2.5-year multicenter study. Graefes. Arch. Clin. Exp. Ophthalmol. (1982) 219:68-71. (Pubitemid 12048172)
25. KENDALL K, MUNDORF T, NARDIN G, ZIMMERMAN T, HESSE R, LAVIN P: Tolerability of timolol and betaxolol in patients with chronic open-angle glaucoma. Clin. Ther. (1987) 9:651-655. (Pubitemid 17166125)
26. AKINGBEHIN T, VILLADA J: Metipranolol-associated granulomatous anterior uveitis. Br. J. Ophthalmol. (1991) 75:519-523.
27. MELLES R, WONG I: Metipranololassociated granulomatous iritis. Am. J. Ophthalmol. (1994) 118:712-715.
28. PATEL N, PATEL K, MOSTER M, SPAETH G: Metipranolol-associated nongranulomatous anterior uveitis. Am. J. Ophthalmol. (1997) 123:843-844. (Pubitemid 27250936)
29. MAAS S, ROS F, DE H, LJ, DE KAISER RJ: Long-term treatment with Pilogel/betablocker in glaucoma patients. Int. Ophthalmol. (1991) 15:281-284.
30. VAN BUSKIRK EM: Corneal anesthesia after timolol maleate therapy. Am. J. Ophthalmol. (1979) 88:739-743.
31. BRANDT J, WITTPENN J, KATZ L, STEINMANN W, SPAETH G: Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am. J. Ophthalmol. (1991) 112:297-301.
32. SHERWOOD M, GRIERSON I, MILLAR L, HITCHINGS R: Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology (1989) 96:327-335. (Pubitemid 19078905)
33. BROADWAY D, GRIERSON I, O'BRIEN C, HITCHINGS R: Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch. Ophthalmol. (1994) 112:1446-1454. (Pubitemid 24350507)
34. NIIYA A, YOKOI N, MATSUMOTO Y et al.: Effect of beta-blocker eyedrops on corneal epithelial barrier function. Ophthalmologica (2000) 214:332-336.
35. KUPPENS E, STOLWIJK T, VAN BEST, J, DE KEIZER R: Topical timolol, corneal epithelial permeability and autofluorescence in glaucoma by fluorophotometry. Graefes. Arch. Clin. Exp. Ophthalmol. (1994) 232:215-220. (Pubitemid 24127408)
36. HERRERAS J, PASTOR J, CALONGE M, ASENSIO V: Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology (1992) 99:1082-1088.
37. BOGER W III, PULIAFITO C, STEINERT R, LANGSTON D: Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology (1978) 85:259-267.
38. BONOMI L, ZAVARISE G, NOYA E, MICHIELETTO S: Effects of timolol maleate on tear flow in human eyes. Albrecht. Von. Graefes. Arch. Klin. Exp. Ophthalmol. (1980) 213:19-22. (Pubitemid 10133692)
39. DE JONG C, STOLWIJK T, KUPPENS E, DE KEIZER R, VAN BEST J: Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes. Arch. Clin. Exp. Ophthalmol. (1994) 232:221-224. (Pubitemid 24127409)
40. SHIMAZAKI J, HANADA K, YAGI Y et al.: Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0.12% unoprostone. Br. J. Ophthalmol. (2000) 84:1250-1254.
41. FIORE P, JACOBS I, GOLDBERG D: Drug-induced pemphigoid. A spectrum of diseases. Arch. Ophthalmol. (1987) 105:1660-1663. (Pubitemid 18009185)
42. WILHELMUS K, MCCULLOCH R, GROSS R: Dendritic keratopathy associated with beta-blocker eyedrops. Cornea (1990) 9:335-337. (Pubitemid 20308063)
43. GARCIA F, BLANCO J, JUSTE S et al.: Contact dermatitis due to levobunolol in eyedrops. Contact Dermatitis (1997) 36:230. (Pubitemid 27197041)
44. KOCH P: Allergic contact dermatitis due to timolol and levobunolol in eyedrops, with no cross-sensitivity to other ophthalmic beta-blockers. Contact Dermatitis (1995) 33:140-141.
45. ZUCCHELLI V, SILVANI S, VEZZANI C, LORENZI S, TOSTI A: Contact dermatitis from levobunolol and befunolol. Contact Dermatitis (1995) 33:66-67.
46. DI LERNIA V, ALBERTINI G, BISIGHINI G: Allergic contact dermatitis from levobunolol eyedrops. Contact Dermatitis (1995) 33:57.
47. VAN JOOST T, MIDDELKAMP J, ROS FE: Dermatitis as a side-effect of long-term topical treatment with certain beta-blocking agents. Br. J. Dermatol. (1979) 101:171-177.
48. BECKMAN K, CHANES L, KAUFMAN S: Lichen planus associated with topical beta-blocker therapy. Am. J. Ophthalmol. (1995) 120:530-531.
49. PUIG L, GONI F, ROQUE A, BORDAS F, DE MORAGAS JM: Psoriasis induced by ophthalmic timolol preparations. Am. J. Ophthalmol. (1989) 108:455-456. (Pubitemid 19259217)
50. FEILER-OFRY V, GODEL V, LAZAR M: Nail pigmentation following timolol maleate therapy. Ophthalmologica (1981) 182:153-156. (Pubitemid 11028257)
51. NETLAND P, WEISS H, STEWART W, COHEN J, NUSSBAUM L: Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am. J. Ophthalmol. (1997) 123:465-477. (Pubitemid 27171851)
52. ANGELO-NIELSEN K: Timolol topically and diabetes mellitus. JAMA (1980) 244:2263. (Pubitemid 11250991)
53. NELSON W, FRAUNFELDER F, SILLS J, ARROWSMITH J, KURITSKY J: Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am. J. Ophthalmol. (1986) 102:606-611. (Pubitemid 17175963)
54. FRAUNFELDER F, MEYER S: Systemic side effects from ophthalmic timolol and their prevention. J. Ocul. Pharmacol. (1987) 3:177-184. (Pubitemid 17134682)
55. JONES F, EKBERG N: Exacerbation of obstructive airway disease by timolol. JAMA (1980) 244:2730. (Pubitemid 11199456)
56. CHUN J, BRODSKY M, ALLEN B: Syncope, bradycardia, and atrioventricular block associated with topical ophthalmic levobunolol. Am. Heart J. (1994) 127:689-690. (Pubitemid 24124703)
57. CHARAN N, LAKSHMINARAYAN S: Pulmonary effects of topical timolol. Arch. Intern. Med. (1980) 140:843-844. (Pubitemid 10120846)
58. SADIQ S, FIELDING K, VERNON S: The effect of timolol drops on respiratory function. Eye (1998) 12(Pt 3a):386-389. (Pubitemid 28359361)
59. DIGGORY P, HEYWORTH P, CHAU G, MCKENZIE S, SHARMA A: Unsuspected bronchospasm in association with topical timolol-a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? Age Ageing (1994) 23:17-21. (Pubitemid 24061421)
60. DIGGORY P, FRANKS W: Glaucoma therapy may take your breath away. Age Ageing (1997) 26:63-67. (Pubitemid 27241278)
61. DIGGORY P, CASSELS-BROWN A, VAIL A, HILLMAN J: Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br. J. Ophthalmol. (1998) 82:146-149. (Pubitemid 28176988)
62. DIGGORY P, CASSELS-BROWN A, VAIL A, ABBEY L, HILLMAN J: Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet (1995) 345:1604-1606.
63. STEWART W, DAY D, HOLMES K, STEWART J: Effect of timolol 0.5% gel and solution on pulmonary function in older glaucoma patients. J. Glaucoma (2001) 10:277-232.
64. STUBBS G: Betagan drops. Med. J. Aust. (1994) 161:576.
65. COLEMAN A, DIEHL D, JAMPEL H, BACHORIK P, QUIGLEY H: Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch. Ophthalmol. (1990) 108:1260-1263. (Pubitemid 20295386)
66. SAFRAN A, SIMONA F, SANSONETTI A, POMETTA D, JAMES R: Topical timolol maleate might adversely affect serum lipoproteins. Int. Ophthalmol. (1993) 17:109-110. (Pubitemid 23263108)
67. FREEDMAN S, FREEDMAN N, SHIELDS M et al.: Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am. J. Ophthalmol. (1993) 116:600-611. (Pubitemid 23337047)
68. YAMAMOTO T, KITAZAWA Y, NOMA A et al.: The effects of the beta-adrenergicblocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J. Glaucoma (1996) 5:252-257. (Pubitemid 26267982)
69. MIRZA G, KARAKUCUK S, TEMEL E: Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. J. Glaucoma (2000) 9:45-50. (Pubitemid 32440550)
70. DUCH S, DUCH C, PASTO L, FERRER P: Changes in depressive status associated with topical beta-blockers. Int. Ophthalmol. (1992) 16:331-335.
71. RAO M, O'BRIEN J, DENING T, DOBER M: Systemic hazards of ocular timolol. Br. J. Hosp. Med. (1993) 50:553.
72. MCMAHON C, SHAFFER R, HOSKINS H JR, HETHERINGTON J JR: Adverse effects experienced by patients taking timolol. Am. J. Ophthalmol. (1979) 88:736-738. (Pubitemid 9256155)
73. VAHIDASSR M, FOY C, O'MALLEY T, PASSMORE A: Eye drops and lethargy. J. R. Soc. Med. (1997) 90:155. (Pubitemid 27135948)
74. MELDON S, EMERMAN C, SCHUBERT D, MOFFA D, ETHEART R: Depression in geriatric ED patients: prevalence and recognition. Ann. Emerg. Med. (1997) 30:141-145. (Pubitemid 27334895)
75. GLYNN R, SEDDON J, KRUG J JR, SAHAGIAN C, CHIAVELLI M, CAMPION E: Falls in elderly patients with glaucoma. Arch. Ophthalmol. (1991) 109:205-210.
76. SCHUMAN J: Effects of systemic betablocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology (2000) 107:1171-1177.
77. EDEKI T, HE H, WOOD A: Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA (1995) 274:1611-1613.
78. ISHII Y, NAKAMURA K, TSUTSUMI K, KOTEGAWA T, NAKANO S, NAKATSUKA K: Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J. Clin. Pharmacol. (2000) 40:193-199.
79. ZIMMERMAN T, WHEELER T: Miotics: side effects and ways to avoid them. Ophthalmology (1982) 89:76-80. (Pubitemid 12173512)
80. EDWARDS RS: A comparative study of Ocusert Pilo 40, intensive pilocarpine and low-dose pilocarpine in the initial treatment of primary acute angle-closure glaucoma. Curr. Med. Res. Opin. (1997) 13:501-509. (Pubitemid 27199152)
81. JOHNSON D, EPSTEIN D, ALLEN R et al.: A one-year multicenter clinical trial of pilocarpine gel. Am. J. Ophthalmol. (1984) 97:723-729. (Pubitemid 14082959)
82. ALPAR J: Miotics and retinal detachment: a survey and case report. Ann. Ophthalmol. (1979) 11:395-401. (Pubitemid 9140161)
83. BEASLEY H, FRAUNFELDER F: Retinal detachments and topical ocular miotics. Ophthalmology (1979) 86:95-98. (Pubitemid 9171540)
84. SCHUMAN J, HERSH P, KYLSTRA J: Vitreous hemorrhage associated with pilocarpine. Am. J. Ophthalmol. (1989) 108:333-334. (Pubitemid 19228979)
85. PAYNE T, THOMAS R: Iridoschisis: a case report. Am. J. Ophthalmol. (1966) 62:966-967.
86. BENEDICT W, SHAMI M: Impending macular hole associated with topical pilocarpine. Am. J. Ophthalmol. (1992) 114:765-766.
87. AXELSSON U, HOLMBERG A: The frequency of cataract after miotic therapy. Acta Ophthalmol. (Copenh) (1966) 44:421-429.
88. DE ROETTH A: Lens opacities in glaucoma patients on phospholine iodide therapy. Trans. Ophthalmol. Soc. UK (1966) 86:89-100.
89. SHAFFER R, HETHERINGTON J JR: Anticholinesterase drugs and cataracts. Trans. Am. Ophthalmol. Soc. (1966) 64:204-216.
90. WRIGHT P: Squamous metaplasia or epidermalization of the conjunctiva as an adverse reaction to topical medication. Trans. Ophthalmol. Soc. UK (1979) 99:244-246. (Pubitemid 10074863)
91. BROADWAY D, GRIERSON I, O'BRIEN C, HITCHINGS R: Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch. Ophthalmol. (1994) 112:1446-1454. (Pubitemid 24350507)
92. CUSANO F, LUCIANO S, CAPOZZI M, VERRILLI D: Contact dermatitis from pilocarpine. Contact Dermatitis (1993) 29:99. (Pubitemid 23226513)
93. GRECO J, KELMAN C: Systemic pilocarpine toxicity in the treatment of angle closure glaucoma. Ann. Ophthalmol. (1973) 5:57-59.
94. LITTMANN L, KEMPLER P, ROHLA M, FENYVESI T: Severe symptomatic atrioventricular block induced by pilocarpine eye drops. Arch. Intern. Med. (1987) 147:586-587. (Pubitemid 17036608)
95. FRAUNFELDER F, MEYER S, BAGBY G JR, DREIS M: Hematologic reactions to carbonic anhydrase inhibitors. Am. J. Ophthalmol. (1985) 100:79-81. (Pubitemid 15003415)
96. MAUS T, LARSSON L, MCLAREN J, BRUBAKER R: Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch. Ophthalmol. (1997) 115:45-49. (Pubitemid 27034930)
97. LARSSON L, ALM A: Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Arch Ophthalmol. (1998) 116:19-24. (Pubitemid 28098890)
98. MARCH W, OCHSNER K: The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am. J. Ophthalmol. (2000) 129:136-143. (Pubitemid 30089271)
99. STRAHLMAN E, TIPPING R, VOGEL: A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, betaxolol. International Dorzolamide Study Group. Arch. Ophthalmol. (1995) 113:1009-1016.
100. ROSENBERG L, KRUPIN T, TANG L, HONG P, RUDERMAN J: Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology (1998) 105:88-92.
101. EPSTEIN R, BROWN S, DENNIS R, KONOWAL-ALLEN A: Combination of systemic acetazolamide and topical dorzolamide. Ophthalmology (1998) 105:1581-1582. (Pubitemid 28513500)
102. ADAMSONS I, OSTROV C, BOYLE J: Two-year safety study of dorzolamide as monotherapy with timolol and pilocarpine. Dorzolamide Safety Study Group. J. Glaucoma (1998) 7:395-401. (Pubitemid 30247084)
103. CLINESCHMIDT C, WILLIAMS R, SNYDER E, ADAMSONS I: A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamidetimolol combination to monotherapy with timolol or dorzolamide. Ophthalmology (1999) 106(12 Suppl.):17-24.
104. HUTZELMANN J, OWENS S, SHEDDEN A, ADAMSONS I, VARGAS E: Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br. J. Ophthalmol. (1998) 82:1249-1259.
105. LASS J, KHOSROF S, LAURENCE J, HORWITZ B, GHOSH K, ADAMSONS I: A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol and betaxolol. Dorzolamide Corneal Effects Study Group. Arch. Ophthalmol. (1998) 116:1003-1010. (Pubitemid 29101823)
106. KONOWAL A, MORRISON J, BROWN S, COOKE D, MAGUIRE L, VERDIER D et al.: Irreversible corneal decompensation in patients treated with topical dorzolamide. Am. J. Ophthalmol. (1999) 127:4.
107. FINEMAN M, KATZ L, WILSON R: Topical dorzolamide-induced hypotony and ciliochoroidal detachment in patients with previous filtration surgery. Arch Ophthalmol. (1996) 114:403-406.
108. VELA M, CAMPBELL D: Hypotony and ciliochoroidal detachment following pharmacologic aqueous suppressant therapy in previously filtered patients. Ophthalmology (1985) 92:50-57. (Pubitemid 15170413)
109. AALTO-KORTE K: Contact allergy to dorzolamide eyedrops. Contact Dermatitis (1998) 39:206. (Pubitemid 28490991)
110. SILVER L: Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am. J. Ophthalmol. (1998) 126:400-408.
111. THOE SCHWARTZENBERG GW, TROPE GE: Anorexia, depression and dementia induced by dorzolamide eyedrops (Trusopt). Can. J. Ophthalmol. (1999) 34:93-94.
112. BALFOUR J, WILDE M: Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging (1997) 10:384-403. (Pubitemid 27202088)
113. CARLSEN J, DURCAN J, ZABRISKIE N, SWARTZ M, CRANDALL A: Nephrolithiasis with dorzolamide. Arch. Ophthalmol. (1999) 117:1087-1088.
114. HODAPP E, KOLKER A, KASS M, GOLDBERG I, BECKER B, GORDON M: The effect of topical clonidine on intraocular pressure. Arch. Ophthalmol. (1981) 99:1208-1211. (Pubitemid 11087066)
115. CRICHTON A: Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine. Can. J. Ophthalmol. (1998) 33:254-255.
116. STEWART W, LAIBOVITZ R, HORWITZ B, STEWART R, RITCH R, KOTTLER M: A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Arch. Ophthalmol. (1996) 114:938-942. (Pubitemid 26271458)
117. LIN S, LIANG S: Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution. J. Ocul. Pharmacol. Ther. (1995) 11:267-278.
118. ARAUJO S, BOND J, WILSON R, MOSTER M, SCHMIDT C JR, SPAETH G: Long term effect of apraclonidine. Br. J. Ophthalmol. (1995) 79:1098-1101. (Pubitemid 26002683)
119. GROSS R, PINYERO A, ORENGONANIA S: Clinical experience with apraclonidine 0.5%. J. Glaucoma (1997) 6:298-302. (Pubitemid 28050921)
120. BUTLER P, MANNSCHRECK M, LIN S, HWANG I, ALVARADO J: Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch. Ophthalmol. (1995) 113:293-296.
121. ROBIN A, RITCH R, SHIN D, SMYTHE B, MUNDORF T, LEHMANN R: Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. Trans. Am. Ophthalmol. Soc. (1995) 120:421-438. Discussion 439-441.
122. SCHUMAN J, HORWITZ B, CHOPLIN N, DAVID R, ALBRACHT D, CHEN K: A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch. Ophthalmol. (1997) 115:847-852.
123. KATZ L: Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily. 1-year results in glaucoma patients. Brimonidine Study Group. Am. J. Ophthalmol. (1999) 127:20-26. (Pubitemid 29036611)
124. STEWART WC, SHARPE ED, HARBIN TS JR et al.: Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am. J. Ophthalmol. (2000) 129:723-727. (Pubitemid 30604149)
125. JAVITT J, GOLDBERG I: Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. J. Glaucoma (2000) 9:398-408. (Pubitemid 32472308)
126. BARNES S, CAMPAGNA J, DIRKS M, DOE E: Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Ophthalmology (1999) 106:2033-2037.
127. THOMPSON C, VACHASPATI P, KOLIS S et al.: A proposed mechanism for paminoclonidine allergenicity based on its relative oxidative lability. Chem. Res. Toxicol. (1997) 10:1032-1036. (Pubitemid 27418020)
128. GORDON R, LIEBMANN J, GREENFIELD D, LAMA P, RITCH R: Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy. Eye (1998) 12(Pt 4):697-700. (Pubitemid 28418579)
129. SHIN D, GLOVER B, CHA S, KIM Y, KIM C, NGUYEN K: Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am. J. Ophthalmol. (1999) 127:511-517.
130. JAVITT J, SCHIFFMAN R: Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. J. Glaucoma (2000) 9:224-234. (Pubitemid 32429363)
131. BERLIN R, LEE U, SAMPLES J et al.: Ophthalmic drops causing coma in an infant. J. Pediatr. (2001) 138:441-443. (Pubitemid 32207156)
132. CARLSEN J, ZABRISKIE N, KWON Y, BARBE M, SCOTT W: Apparent central nervous system depression in infants after the use of topical brimonidine. Am. J. Ophthalmol. (1999) 128:255-256. (Pubitemid 29379793)
133. KATZ L: Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J. Glaucoma (2002) 11:119-126. (Pubitemid 34298592)
134. ALM A, CAMRAS C, WATSON P: Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv. Ophthalmol. (1997) 41(Suppl. 2):S105-S110. (Pubitemid 27154533)
135. WATSON P: Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology (1998) 105:82-87. (Pubitemid 28070605)
136. ALM A, WIDENGARD I: Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol. Scand. (2000) 78:71-76. (Pubitemid 30095316)
137. WISTRAND P, STJERNSCHANTZ J, OLSSON K: The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Ophthalmol. (1997) 41(Suppl. 2):S129-S138. (Pubitemid 27154537)
138. CAMRAS C, NEELY D, WEISS E: Latanoprost-induced iris color darkening: a case report with long-term follow-up. J. Glaucoma (2000) 9:95-98. (Pubitemid 32440557)
139. GRIERSON I, CRACKNELL K, PFEIFFER N: The iris after prostanoid treatment. Curr. Opin. Ophthalmol. (2001) 12:112-118. (Pubitemid 32232082)
140. JOHNSTONE M: Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am. J. Ophthalmol. (1997) 124:544-547. (Pubitemid 27425878)
141. MANSBERGER S, CIOFFI G: Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch. Ophthalmol. (2000) 118:718-719. (Pubitemid 30327353)
142. KOOK M, LEE K: Increased eyelid pigmentation associated with use of latanoprost. Am. J. Ophthalmol. (2000) 129:804-806. (Pubitemid 30604165)
143. WAND M, RITCH R, ISBEY E JR, ZIMMERMAN T: Latanoprost and periocular skin color changes. Arch. Ophthalmol. (2001) 119:614-615. (Pubitemid 32293569)
144. WAND M, GILBERT C, LIESEGANG T: Latanoprost and herpes simplex keratitis. Am. J. Ophthalmol. (1999) 127:602-604. (Pubitemid 29215774)
145. EKATOMATIS P: Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br. J. Ophthalmol. (2001) 85:1008-1009. (Pubitemid 32706180)
146. GADDIE I, BENNETT D: Cystoid macular edema associated with the use of latanoprost. J. Am. Optom. Assoc. (1998) 69:122-128.
147. AYYALA R, CRUZ D, MARGO C et al.: Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am. J. Ophthalmol. (1998) 126:602-604. (Pubitemid 28475931)
148. MOROI S, GOTTFREDSDOTTIR M, SCHTEINGART M et al.: Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology (1999) 106:1024-1029. (Pubitemid 30191566)
149. SCHUMER R, CAMRAS C, MANDAHL A: Latanoprost and cystoid macular edema: is there a causal relation? Curr. Opin. Ophthalmol. (2000) 11:94-100. (Pubitemid 30164028)
150. WARDROP D, WISHART P: Latanoprost and cystoid macular oedema in a pseudophake. Br. J. Ophthalmol. (1998) 82:843-844. (Pubitemid 28376924)
151. THORNE J, MAGUIRE A, LANCIANO R: CME and anterior uveitis with latanoprost use. Ophthalmology (1998) 105:1981-1983.
152. WARWAR R, BULLOCK J: Latanoprostinduced uveitis. Surv. Ophthalmol. (1999) 43:466-468.
153. WARWAR R, BULLOCK J, BALLAL D: Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology (1998) 105:263-268. (Pubitemid 28090830)
154. HEDNER J, EVERTS B, MOLLER C: Latanoprost and respiratory function in asthmatic patients: randomized, doublemasked, placebo-controlled crossover evaluation. Arch. Ophthalmol. (1999) 117:1305-1309. (Pubitemid 30029340)
155. WESTON B: Migraine headache associated with latanoprost. Arch. Ophthalmol. (2001) 119:300-301.
156. SUSANNA R JR, MEDEIROS FA: The pros and cons of different prostanoids in the medical management of glaucoma. Curr. Opin. Ophthalmol. (2001) 12:1039-1042.
157. YAMAMOTO T, KITAZAWA Y: Iris-color change developed after topical isopropyl unoprostone treatment. J. Glaucoma (1997) 6:430-432. (Pubitemid 28051080)
158. NETLAND P, LANDRY T, SULLIVAN E et al.: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. (2001) 132:472-484. (Pubitemid 32904567)
159. WOODWARD D, KRAUSS A, CHEN J et al.: The pharmacology of bimatoprost (Lumigan). Surv. Ophthalmol. (2001) 45(Suppl. 44):S337-S345.
160. BRUBAKER R, SCHOFF E, NAU C, CARPENTER S, CHEN K, VANDENBURGH A: Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol. (2001) 131:19-24. (Pubitemid 32037003)
161. SHERWOOD M, BRANDT J: Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. (2001) 45(Suppl. 4):S361-4S368.
162. BRANDT J, VANDENBURGH A, CHEN K, WHITCUP S: Comparison of once-or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology (2001) 108:1023-1031. (Pubitemid 32500015)
163. LIN L, GALIN M, OBSTBAUM S, KATZ I: Longterm timolol therapy. Surv. Ophthalmol. (1979) 23:377-380. (Pubitemid 9199793)
164. KROLL DM, SCHUMAN JS: Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am. J. Ophthalmol. (2002) 133:401-403. (Pubitemid 34171592)